ArticleCNS neuroscience & therapeutics2025
CircMAN1A2 Levels Determine GBM Susceptibility to TMZ in a Pathway Involving TEP1- and KEAP1-Mediated NRF2 Degradation Leading to Ferroptosis.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- CircRNA-mediated regulation of ferroptosis in cancer: mechanistic networks and therapeutic implications.Cancer gene therapy · 2026Review
- Ferroptosis in Glioblastoma and Neuroblastoma: Molecular Mechanisms and Novel Therapeutic Strategies.Current issues in molecular biology · 2026Review
- Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma.Frontiers in immunology · 2026Article
- Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks.Frontiers in oncology · 2026Review
- Ferroptosis and metabolic reprogramming in the immunosuppressive microenvironment of glioblastoma: emerging mechanisms and novel strategies.Frontiers in immunology · 2026Review
- Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.Frontiers in pharmacology · 2026Article
- CircMAN1A2 Levels Determine GBM Susceptibility to TMZ in a Pathway Involving TEP1- and KEAP1-Mediated NRF2 Degradation Leading to Ferroptosis.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis and resistance to temozolomide (TMZ). The role of downregulated circular RNAs (circRNAs) in GBM progression remains unclear.
methodsCircRNA sequencing and public dataset analysis identified dysregulated circRNAs in GBM. Functional assays were conducted in patient-derived glioma stem-like cells (GSCs) with circMAN1A2 overexpression or knockdown. Ferroptosis-related experiments, protein interaction assays, and in vivo mouse models were used to explore mechanisms and therapeutic effects.
resultsCircMAN1A2 was significantly downregulated in GBM tissues and inversely correlated with WHO grade and patient survival. Overexpression of circMAN1A2 inhibited GSC proliferation, stemness, invasion, and reversed TMZ resistance by inducing ferroptosis. Mechanistically, circMAN1A2 was regulated by PRPF40B and directly bound to TEP1, disrupting its interaction with KEAP1, thereby promoting NRF2 degradation and ferroptosis. NRF2 upregulated ANXA1, which promoted tumor-associated macrophage (TAM) recruitment and M2 polarization. In vivo, circMAN1A2 overexpression suppressed tumor growth, enhanced TMZ sensitivity, and reduced NRF2/ANXA1 expression, effects reversed by TEP1.
conclusionsCircMAN1A2 suppresses GBM progression and TMZ resistance by inducing ferroptosis and modulating the TEP1-KEAP1-NRF2-ANXA1 axis. It represents a potential therapeutic target in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.